Takeda's Rozerem To Launch In September Following FDA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Ramelteon clears FDA for "treatment of insomnia characterized by difficulty with sleep onset." Takeda is positioning Rozerem as the only prescription insomnia agent that does not carry controlled substance scheduling.
You may also be interested in...
Leave It To Beaver: Rozerem DTC Campaign Boosts New Rx Share
Takeda sleep aid’s new Rx share has grown more than 50% since campaign began.
Leave It To Beaver: Rozerem DTC Campaign Boosts New Rx Share
Takeda sleep aid’s new Rx share has grown more than 50% since campaign began.
Rozerem DTC Ads Highlight Low Abuse Potential Of Sleep Aid
Takeda launches Rozerem TV spots promoting sweet dreams with a humorous approach.